(Q57265716)

English

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†

scientific article published on 04 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

Prudence Francis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Evandro de Azambuja

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

C Oakman

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Crown

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Quinaux

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Buyse

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Margeli Vila

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Andersson

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

B Nordenskjöld

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Jakesz

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

B Thürlimann

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Gutiérrez

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

V Harvey

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

L Punzalan

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

P Dell'orto

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

D Larsimont

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

I Steinberg

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R D Gelber

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Piccart-Gebhart

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

G Viale

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

4 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1203-1211

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Adjuvant docetaxel for high-risk, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Is adjuvant chemotherapy useful for women with luminal a breast cancer?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS627

21 January 2018

Identifiers

10.1093/ANNONC/MDS627

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293111%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57265716&oldid=2133852717"